OncoMatch/Clinical Trials/NCT04298008
AZD6738 Plus Durvalumab in Biliary Tract Cancer
Is NCT04298008 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including AZD6738 and Durvalumab for bile duct cancer.
Treatment: AZD6738 · Durvalumab — This trial will enroll advanced biliary tract cancer patients who have been previously treated with immunotherapy in either the 2nd or 3rd line. Patients will be treated with AZD6738 and Durvalumab combination.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: immunotherapy — advanced
Cannot have received: atr inhibitor
Lab requirements
Blood counts
Haemoglobin ≥9.0 g/dL; ANC ≥ 1.5 x 10^9/L; Platelet count ≥ 100 x 10^9/L
Kidney function
Creatinine clearance estimated ≥51 mL/min using Cockcroft-Gault equation or 24 hour urine test
Liver function
Serum bilirubin ≤1.5 x institutional ULN (except Gilbert's syndrome); AST (SGOT)/ALT (SGPT) ≤2.5 x ULN unless liver metastases are present, in which case ≤5x ULN
Cardiac function
Mean resting corrected QT interval (QTc) >470 msec for females and >450 for men, obtained from 3 ECGs 2-5 minutes apart using the Fredericia formula [excluded]
Adequate normal organ and marrow function...; Mean QT interval: Mean resting corrected QT interval (QTc) >470 msec for females and >450 for men, obtained from 3 ECGs 2-5 minutes apart using the Fredericia formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify